These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18411320)

  • 1. Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.
    Kanellakopoulou K; Thivaios GC; Kolia M; Dontas I; Nakopoulou L; Dounis E; Giamarellos-Bourboulis EJ; Andreopoulos A; Karagiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2335-9. PubMed ID: 18411320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report.
    Conde-Díaz C; Llenas-García J; Parra Grande M; Terol Esclapez G; Masiá M; Gutiérrez F
    J Med Case Rep; 2017 Feb; 11(1):48. PubMed ID: 28219414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.
    Koort JK; Mäkinen TJ; Suokas E; Veiranto M; Jalava J; Knuuti J; Törmälä P; Aro HT
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1502-8. PubMed ID: 15793132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Shinners E
    J Infect Dis; 1985 Feb; 151(2):291-4. PubMed ID: 3155780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro study of composites of poly(L-lactide-co-ε-caprolactone), β-tricalcium phosphate and ciprofloxacin intended for local treatment of osteomyelitis.
    Ahola N; Männistö N; Veiranto M; Karp M; Rich J; Efimov A; Seppälä J; Kellomäki M
    Biomatter; 2013; 3(2):. PubMed ID: 23507926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant.
    Koort JK; Makinen TJ; Suokas E; Veiranto M; Jalava J; Tormala P; Aro HT
    Acta Orthop; 2008 Apr; 79(2):295-301. PubMed ID: 18484258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus treated with a polylactide carrier releasing linezolid.
    Tsiolis P; Giamarellos-Bourboulis EJ; Mavrogenis AF; Savvidou O; Lallos SN; Frangia K; Lazarettos I; Nikolaou V; Efstathopoulos NE
    Surg Infect (Larchmt); 2011 Apr; 12(2):131-5. PubMed ID: 21348763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoporous silica coatings as a drug delivery system for ciprofloxacin: outcome of variable release rates in the infected middle ear of rabbits.
    Hesse D; Ehlert N; Lüenhop T; Smoczek A; Glage S; Behrens P; Müller PP; Esser KH; Lenarz T; Stieve M; Bleich A; Prenzler NK
    Otol Neurotol; 2013 Aug; 34(6):1138-45. PubMed ID: 23598698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler.
    Mäkinen TJ; Veiranto M; Lankinen P; Moritz N; Jalava J; Törmälä P; Aro HT
    J Antimicrob Chemother; 2005 Dec; 56(6):1063-8. PubMed ID: 16234335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan) releasing moxifloxacin.
    Kanellakopoulou K; Galanopoulos I; Soranoglou V; Tsaganos T; Tziortzioti V; Maris I; Papalois A; Giamarellou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2009 Apr; 33(4):354-9. PubMed ID: 19097865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment.
    Koort JK; Suokas E; Veiranto M; Mäkinen TJ; Jalava J; Törmälä P; Aro HT
    J Biomed Mater Res A; 2006 Sep; 78(3):532-40. PubMed ID: 16736479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
    Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
    Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Processing and sustained in vitro release of rifampicin containing composites to enhance the treatment of osteomyelitis.
    Ahola N; Veiranto M; Männistö N; Karp M; Rich J; Efimov A; Seppälä J; Kellomäki M
    Biomatter; 2012; 2(4):213-25. PubMed ID: 23507887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin.
    Kanellakopoulou K; Galanakis N; Giamarellos-Bourboulis EJ; Rifiotis C; Papakostas K; Andreopoulos A; Dounis E; Karagianakos P; Giamarellou H
    J Antimicrob Chemother; 2000 Aug; 46(2):311-4. PubMed ID: 10933660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation.
    El-Kamel AH; Baddour MM
    Drug Deliv; 2007 Aug; 14(6):349-56. PubMed ID: 17701524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.
    Alvarez H; Castro C; Moujir L; Perera A; Delgado A; Soriano I; Evora C; Sánchez E
    J Biomed Mater Res B Appl Biomater; 2008 Apr; 85(1):93-104. PubMed ID: 17696153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mandibular osteomyelitis due to Pseudomonas aeruginosa. Case report.
    Pappalardo S; Tanteri L; Brutto D; Marescalco M; Carlino V; Consolo G; Mauro M; Cappello V
    Minerva Stomatol; 2008 Jun; 57(6):323-9. PubMed ID: 18617880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model.
    Owusu-Ababio G; Rogers JA; Morck DW; Olson ME
    J Med Microbiol; 1995 Nov; 43(5):368-76. PubMed ID: 7563002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.